Clinical Trial: Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer

This study is no longer recruiting patients.

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Increasing knowledge about the complementary or alternative medicine practices used by women who are at increased risk for breast cancer may provide useful information for planning breast-cancer-prevention strategies. PURPOSE: Clinical trial to determine how many women who are at increased risk for breast cancer use complementary or alternative medicine.

Condition
prevention of breast cancer

MedlinePlus consumer health information 

Study Type: Observational
Study Design: Natural History

Official Title: Study of the Use of Complementary and Alternative Medicine Practices by Women at Increased Risk for Breast Cancer

Further Study Details: 

Study start: June 2000

OBJECTIVES: I. Determine the prevalence of complementary or alternative medicine (CAM) practices among adult women enrolled in the Risk Assessment Clinic at the National Naval Medical Center Breast Care Center and found to be at increased risk for developing breast cancer. II. Correlate the use of CAM with individual risk for breast cancer. III. Define the types of CAM practices used by this study population. IV. Identify reasons why this study population is using CAM.

PROTOCOL OUTLINE: Patients are stratified according to prevalence of complementary and alternative medicine practices (enteral/parenteral vs psycho/neurologic). Patients complete a Personal Risk Assessment form, pre-test/post-test knowledge questionnaires, and a survey questionnaire.

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 2 years.

Eligibility

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

--Prior/Concurrent Therapy--

  • Not specified

--Patient Characteristics--

  • Age: 18 and over
  • Sex: Female
  • Menopausal status: Not specified
  • Performance status: Not specified
  • Life expectancy: Not specified
  • Hematopoietic: Not specified
  • Hepatic: Not specified
  • Renal: Not specified
  • Other: No other prior cancer, except ductal carcinoma in situ or basal cell carcinoma; Able to read and understand English

Location Information


Maryland
      Medicine Branch, Bethesda,  Maryland,  20892,  United States

      National Naval Medical Center, Bethesda,  Maryland,  20889-5000,  United States

Study chairs or principal investigators

Paula Glauber,  Study Chair,  National Cancer Institute (NCI)   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000067716; NCI-00-C-0039; MB-NAVY-B99-088
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  July 11, 2001
ClinicalTrials.gov Identifier:  NCT00020098
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005